Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2011-03-29
2011-03-29
Noakes, Suzanne M (Department: 1656)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C514S002600
Reexamination Certificate
active
07915384
ABSTRACT:
Chimeric peptides or fusion proteins are disclosed that include a RhoGAP activity domain and at least one specificity domain that targets a specific Rho protein. The fusion proteins can be used to inhibit any GTPase activity within a cell. The fusion proteins are particularly advantageous for the treatment of cancer. The present invention generally relates to chimeric peptides capable of regulating GTPases, and more particularly, to methods of targeting individual GTPases by using GTPase-activating proteins. Such proteins may be used for the treatment of cancers and other GTPase-related diseases. This invention relates to nucleic acid molecules and the encoded GTPase activating proteins, and variants thereof, and to the use of these molecules in the characterization, diagnosis, prevention, and treatment of cell signaling, immune, and cell proliferative disorders, particularly cancer. Disclosed herein are compounds and methods for regulating transcription of a selected gene.
REFERENCES:
patent: 4997834 (1991-03-01), Muro et al.
patent: 5492898 (1996-02-01), Bertics et al.
patent: 6117850 (2000-09-01), Patchen et al.
patent: 6451825 (2002-09-01), Uehata et al.
patent: 6620591 (2003-09-01), Dunlay et al.
patent: 6642263 (2003-11-01), Sun et al.
patent: 2467557 (2003-05-01), None
patent: WO 97/30992 (1997-08-01), None
patent: WO 99/40783 (1999-08-01), None
patent: WO 01/78761 (2001-10-01), None
patent: WO 01/83745 (2001-11-01), None
patent: WO 01/93900 (2001-12-01), None
patent: WO 01/97608 (2001-12-01), None
patent: WO 03/011277 (2003-02-01), None
patent: WO 03/042239 (2003-05-01), None
patent: WO 2004/091654 (2004-10-01), None
patent: WO 2005/017160 (2005-02-01), None
patent: WO 2005/056024 (2005-06-01), None
Wang et al. (The GTPase and Rho GAP Domains of p190, a Tumor Suppressor Protein That Binds the Mr 120,000 Ras GAP, Independently Function as Anti-Ras Tumor Suppressors, Cancer Research, 57: 2478-2484, Jun. 15, 1997).
Abo et al., Activation of the NADPH oxidase involves the small GTP-binding protein p21rac1., Nature, 1991, vol. 353, Issue 6345, pp. 668-670.
Allen, W.E. et al., A role for Cdc42 in macrophage chemotaxis., J Cell Biol, 1998, vol. 141, Issue 5, pp. 1147-1157.
Benard et al., Characterization of Rac and Cdc42 Activation in Chemoattractant-stimulated Human Neutrophils Using a Novel Assay for Active GTPases, J. Biol. Chem, 1999, vol. 274, Issue 19, pp. 13198-13204.
Chieregatti et al., Myr 7 is a novel myosin IX-RhoGAP expressed in rat brain, Journal of Cell Science, 1998, vol. 111, pp. 3597-3608.
Croker et al., The Rac2 guanosine triphosphatase regulates B lymphocyte antigen receptor responses and chemotaxis and is required for establishment of B-1a and marginal zone B lymphocytes., J. Immunol., Apr. 2002, vol. 168, Issue 7, pp. 3376-3386.
Del Pozo et al., Integrins regulate GTP-Rac localized effector interactions through dissociation of Rho-GDI., Nat Cell Biol, Mar. 2002, vol. 4, Issue 3, pp. 232-239.
Diekmann et al., Rac GTPase interacts with GAPs and target proteins through multiple effector sites., EMBO J., Nov. 1995, vol. 14, Issue 21, pp. 5297-5305.
EP Office Action dated May 14, 2007 for European Patent Application No. 04781185.6.
Etienne-Manneville et al., Rho GTPases in cell biology., Nature, 2002, vol. 420, Issue 6916, pp. 629-635.
File History of U.S. Appl. No. 10/918,328, as of Jun. 21, 2007.
File History of U.S. Appl. No. 10/918,328, for the period of Jun. 22, 2007-Sep. 18, 2007.
File History of U.S. Appl. No. 11/003,935, as of Jun. 21, 2007.
File History of U.S. Appl. No. 11/003,935, for the period of Jun. 22, 2007-Sep. 18, 2007.
Fritz et al., Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters, British Journal of Cancer, 2002, vol. 87, pp. 635-644.
Gao Yuan et al., Rational design and characterization of a Rac GTPase-specific small molecule inhibitor, Proceedings of the National Academy of Sciences of the United States of America, May 18, 2004, vol. 101, Issue 20, pp. 7618-7623.
Gottig et al., Role of the monomeric GTPase Rho in hematopoietic progenitor cell migration and transplantation, Eur. J. Immunol, 2006, vol. 36, pp. 180-189.
Gu et al., Deletion of a DNA polymerase beta gene segment in T cells using cell type-specific gene targeting., Science, Jul. 1994, vol. 265, Issue 5168, pp. 103-106.
Gu Yi et al., Hematopoietic cell regulation by Rac1 and Rac2 guanosine triphosphates, Science, 2003, vol. 302, Issue 5644, pp. 445-449.
Gu, Y. et al., Rac2, a hematopoiesis-specific Rho GTPase, specifically regulates mast cell protease gene expression in bone marrow-derived mast cells, Mollecular and Cellular Biology, Nov. 2002, vol. 22, Issue 21, pp. 7645-7657.
Gu, Y. et al., RhoH, a hematopoietic-specific Rho GTPase, regulates proliferation, survival, migration and engraftment of hematopoietic progenitor cells, Hematopoiesis, Feb. 2005, vol. 105, Issue 4, pp. 1467-1475.
Hakoshima, T. et al., Structural Basis of the Rho GTPase signaling, J. Biochem., 2003, vol. 134, pp. 327-331.
Hall, Rho GTPases and the actin cytoskeleton., Science. Jan. 1998, vol. 279, Issue 5350, pp. 509-514.
Henschler et al., SDF-1 alpha-induced intracellular calcium transient involves Rho GTPase signalling and is required for migration of hematopoietic progenitor cells, Bioch. And Biophys. Res. Com., 2003, vol. 311, pp. 1067-1071.
Innocenti et al., Phosphoinositide 3-kinase activates Rac by entering in a complex with Eps8, Abi1, and Sos-1., J Cell Biol, Jan. 2003, vol. 160, Issue 1, pp. 17-23.
International Search Report dated Feb. 2, 2005 for PCT Application No. PCT/US2004/026493.
Judkins et al., Single nucleotide polymorphisms in clinical genetic testing: the characterization of the clinical significance of genetic variants and their application in clinical research fro BRCA1, Mutation Research, 2005, vol. 573, pp. 168-179.
Kennedy et al., The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal., Genes Dev, Mar. 1997, vol. 11, Issue 6, pp. 701-713.
Kisselev, Structure, 2002, vol. 10, pp. 8-9.
Knaus et al., Regulation of phagocyte oxygen radical production by the GTP-binding protein Rac 2., Science, Dec. 1991, vol. 254, Issue 5037, pp. 1512-1515.
Li et al., Role of the guanosine triphosphatase Rac2 in T helper 1 cell differentiation., Science, Jun. 2000, vol. 288, Issue 5474, pp. 2219-2222.
Li, X. et al., The hematopoiesis-specific GTP-binding protein RhoH is GTPase deficient and modulates activities of other Rho GTPases by an inhibitory function., Molecular and Cellular Biology, Feb. 2002, vol. 22, Issue 4, pp. 1158-1171.
Llevadot, J. et al., HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells, J. Clin. Investig., Aug. 2001, vol. 108, Issue 3, pp. 399-405.
Michaelson et al., Differential localization of Rho GTPases in live cells: regulation by hypervariable regions and RhoGDI binding, Journal of Cell Biology, Jan. 2001, vol. 152, Issue 1, pp. 11-126.
Minden et al., Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK., Science, Dec. 1994, vol. 266, Issue 5191, pp. 1719-1732.
Moebest et al., Blood, Nov. 2000, vol. 96, Issue 11, part 1, pp. 687a.
Moll et al., The murine rac1 gene: cDNA cloning, tissue distribution and regulated expression of rac1 mRNA by disassembly of actin microfilaments., Oncogene, May 1991, vol. 6, Issue 5, pp. 863-866.
Moon et al., Rho GTPase-activating proteins in cell regulation, Trends in Cell Biology, Jan. 2003, vol. 13, Issue 1, pp. 13-22.
Narumiya et al., rho gene products, botulinum C3 exoenzyme and cell adhesion, Cell. Signal., 1993, vol. 5, Issue 1, pp. 9-19.
Ngo et al., The Protein Folding Problem and Tertiary Structure Prediction, 1994, pp. 433 and 492-495.
Nobes et al., Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia., Cell, Apr. 1995, vol. 81, Issue 1, pp. 53-62.
Olson et al., An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1., Science, Sep. 1995, vol. 269, Issue 5228, pp
Williams David A.
Zheng Yi
Children's Hospital Medical Center
Knobbe Martens Olson & Bear LLP
Lee Jae W
Noakes Suzanne M
LandOfFree
Chimeric peptides for the regulation of GTPases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric peptides for the regulation of GTPases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric peptides for the regulation of GTPases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2780206